These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

632 related articles for article (PubMed ID: 33771887)

  • 1. A cross-talk between CAR T cell subsets and the tumor microenvironment is essential for sustained cytotoxic activity.
    Boulch M; Cazaux M; Loe-Mie Y; Thibaut R; Corre B; Lemaître F; Grandjean CL; Garcia Z; Bousso P
    Sci Immunol; 2021 Mar; 6(57):. PubMed ID: 33771887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of VISTA regulated via IFN-γ governs endogenous T-cell function and exhibits correlation with the efficacy of CD19 CAR-T cell treated B-malignant mice.
    Tang D; Zhao L; Yan F; Ren C; Xu K; Zhao K
    J Immunother Cancer; 2024 Jun; 12(6):. PubMed ID: 38925679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential role of Th1 and Th2 cytokines in autotoxicity driven by CD19-specific second-generation chimeric antigen receptor T cells in a mouse model.
    Cheadle EJ; Sheard V; Rothwell DG; Bridgeman JS; Ashton G; Hanson V; Mansoor AW; Hawkins RE; Gilham DE
    J Immunol; 2014 Apr; 192(8):3654-65. PubMed ID: 24623129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells.
    An N; Tao Z; Li S; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
    Oncotarget; 2016 Mar; 7(9):10638-49. PubMed ID: 26840021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Vivo Generation of CAR T Cells Selectively in Human CD4
    Agarwal S; Hanauer JDS; Frank AM; Riechert V; Thalheimer FB; Buchholz CJ
    Mol Ther; 2020 Aug; 28(8):1783-1794. PubMed ID: 32485137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD19 Chimeric Antigen Receptor T Cells From Patients With Chronic Lymphocytic Leukemia Display an Elevated IFN-γ Production Profile.
    Magalhaes I; Kalland I; Kochenderfer JN; Österborg A; Uhlin M; Mattsson J
    J Immunother; 2018; 41(2):73-83. PubMed ID: 29315094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer.
    Mohammed S; Sukumaran S; Bajgain P; Watanabe N; Heslop HE; Rooney CM; Brenner MK; Fisher WE; Leen AM; Vera JF
    Mol Ther; 2017 Jan; 25(1):249-258. PubMed ID: 28129119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
    Kosti P; Maher J; Arnold JN
    Front Immunol; 2018; 9():1104. PubMed ID: 29872437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric Antigen Receptor-Engineered Human Gamma Delta T Cells: Enhanced Cytotoxicity with Retention of Cross Presentation.
    Capsomidis A; Benthall G; Van Acker HH; Fisher J; Kramer AM; Abeln Z; Majani Y; Gileadi T; Wallace R; Gustafsson K; Flutter B; Anderson J
    Mol Ther; 2018 Feb; 26(2):354-365. PubMed ID: 29310916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual Effects of Cyclooxygenase Inhibitors in Combination With CD19.CAR-T Cell Immunotherapy.
    Yang M; Wang L; Ni M; Neuber B; Wang S; Gong W; Sauer T; Schubert ML; Hückelhoven-Krauss A; Xia R; Ge J; Kleist C; Eckstein V; Sellner L; Müller-Tidow C; Dreger P; Schmitt M; Schmitt A
    Front Immunol; 2021; 12():670088. PubMed ID: 34122428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-Specific Reactive Oxygen Species Accelerators Improve Chimeric Antigen Receptor T Cell Therapy in B Cell Malignancies.
    Yoo HJ; Liu Y; Wang L; Schubert ML; Hoffmann JM; Wang S; Neuber B; Hückelhoven-Krauss A; Gern U; Schmitt A; Müller-Tidow C; Dreger P; Mokhir A; Schmitt M; Sellner L
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31109083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcomes of Sleeping Beauty-generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas.
    Srour SA; Singh H; McCarty J; de Groot E; Huls H; Rondon G; Qazilbash M; Ciurea S; Bardelli G; Buck J; Alousi A; Nieto Y; Rezvani K; Marin D; Popat U; Hosing C; Shpall EJ; Wierda WG; Kantarjian H; Champlin RE; Cooper LJ; Kebriaei P
    Blood; 2020 Mar; 135(11):862-865. PubMed ID: 31961918
    [No Abstract]   [Full Text] [Related]  

  • 13. Immunological Synapse Predicts Effectiveness of Chimeric Antigen Receptor Cells.
    Xiong W; Chen Y; Kang X; Chen Z; Zheng P; Hsu YH; Jang JH; Qin L; Liu H; Dotti G; Liu D
    Mol Ther; 2018 Apr; 26(4):963-975. PubMed ID: 29503199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CAR T Cells Generated Using Sleeping Beauty Transposon Vectors and Expanded with an EBV-Transformed Lymphoblastoid Cell Line Display Antitumor Activity In Vitro and In Vivo.
    Chicaybam L; Abdo L; Carneiro M; Peixoto B; Viegas M; de Sousa P; Fornazin MC; Spago MC; Albertoni Laranjeira AB; de Campos-Lima PO; Nowill A; Barros LRC; Bonamino MH
    Hum Gene Ther; 2019 Apr; 30(4):511-522. PubMed ID: 30793967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The altering cellular components and function in tumor microenvironment during remissive and relapsed stages of anti-CD19 CAR T-cell treated lymphoma mice.
    Zhao K; Ren C; Tang D; Zhao L; Chen X; Wang Y; Xu K
    Front Immunol; 2023; 14():1101769. PubMed ID: 36761733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors.
    Parihar R; Rivas C; Huynh M; Omer B; Lapteva N; Metelitsa LS; Gottschalk SM; Rooney CM
    Cancer Immunol Res; 2019 Mar; 7(3):363-375. PubMed ID: 30651290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical Assessment of Suitable Natural Killer Cell Sources for Chimeric Antigen Receptor Natural Killer-Based "Off-the-Shelf" Acute Myeloid Leukemia Immunotherapies.
    Kloess S; Oberschmidt O; Dahlke J; Vu XK; Neudoerfl C; Kloos A; Gardlowski T; Matthies N; Heuser M; Meyer J; Sauer M; Falk C; Koehl U; Schambach A; Morgan MA
    Hum Gene Ther; 2019 Apr; 30(4):381-401. PubMed ID: 30734584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Granzyme B-activated IL18 potentiates αβ and γδ CAR T cell immunotherapy in a tumor-dependent manner.
    Hull CM; Larcombe-Young D; Mazza R; George M; Davies DM; Schurich A; Maher J
    Mol Ther; 2024 Jul; 32(7):2373-2392. PubMed ID: 38745414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors.
    Kochenderfer JN; Rosenberg SA
    Nat Rev Clin Oncol; 2013 May; 10(5):267-76. PubMed ID: 23546520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-CD19 CAR T cells potently redirected to kill solid tumor cells.
    Ambrose C; Su L; Wu L; Dufort FJ; Sanford T; Birt A; Hackel BJ; Hombach A; Abken H; Lobb RR; Rennert PD
    PLoS One; 2021; 16(3):e0247701. PubMed ID: 33735268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.